Research Desk Line-up: ResMed Post Earnings Coverage
LONDON, UK / ACCESSWIRE / August 11, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Varian Medical Systems, Inc. (NYSE: VAR), following which we have published a free report that can be viewed by signing up at http://protraderdaily.com/optin/?symbol=VAR. The Company announced on August 09, 2017, that it has signed an agreement with Bionix® Radiation Therapy to become the non-exclusive distributor of Bionix®'s brachytherapy applicators. As a Bionix® distributor, Varian will market the Bionix® Esophageal Applicator (E-App™) and the Anorectal Applicator (AR-1™) across North America. For immediate access to our complimentary reports, including today's coverage, register for free now at:
http://protraderdaily.com/register/
Discover more of our free reports coverage from other companies within the Medical Appliances & Equipment industry. Pro-TD has currently selected ResMed Inc. (NYSE: RMD) for due-diligence and potential coverage as the Company announced on August 01, 2017, its financial results for Q4 FY17. Tune in to our site to register for a free membership, and be among the early birds that get our report on ResMed when we publish it.
At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on VAR; also brushing on RMD. Go directly to your stock of interest and access today's free coverage at:
http://protraderdaily.com/optin/?symbol=VAR
http://protraderdaily.com/optin/?symbol=RMD
None of the Companies have disclosed the financial details and other terms of the distribution agreement so far.
Commenting on being appointed as the distributor of Bionix®'s brachytherapy applicators, Thomas Pollatz, Director of Brachytherapy Marketing at Varian Medical Systems said:
"We are pleased to partner with Bionix® to provide cancer specialists with an expanded portfolio of innovative brachytherapy applicators. he Bionix® AR-1 and E-App applicators are complementary to Varian's current applicator family and increase treatment options aimed at providing the best treatment solution for the patient."
David Hart, President of Bionix® Radiation Therapy, added:
"We are thrilled to work with Varian Medical in providing disruptive brachytherapy applicators to better serve patients."
About Bionix®'s Brachytherapy Applicators
Brachytherapy, also known as internal radiotherapy, is a form of radiation therapy where a sealed radiation source is placed inside or next to the area requiring treatment. Brachytherapy can be used alone or in combination with other therapies such as surgery, External Bram Radiation Therapy (EBRT) and chemotherapy. Brachytherapy represents an effective treatment option for many types of cancer. Treatment results have demonstrated that the cancer cure rates of brachytherapy are either comparable to surgery and EBRT or are improved when used in combination with these techniques. In addition, brachytherapy is associated with a low risk of serious adverse side effects.
Bionix®'s AR-1 and E-App are both disposable brachytherapy applicators. The AR-1 is designed specifically for the treatment of anal and rectal cancers, whereas E-App is designed specifically for the treatment of upper GI (gastrointestinal) cancers.
The AR-1 has a dual balloon design which allows exophytic tumors to press closer to the source catheter. This creates the ability to deliver a very high dose to the tumor surface while sparing healthy tissue. The AR-1 is a simple way to treat anal or rectal tumors in a way that cannot be achieved with external beam therapy.
The E-App, on the other hand, has five independently operable balloons. These balloons maintain the central position of the source catheter in both straight and curved anatomy, allowing for closer proximity of the target to the source while maintaining distance from healthy tissue.
About Varian Medical Systems
Palo Alto, California based Varian Medical Systems is the world's leading manufacturer of medical devices and software for treating and managing cancer. The Company has a robust product portfolio and has long-standing relationships with the world's leading clinicians. It has over 70 sales and support offices worldwide and is supported by a global team of over 6,600 employees.
About Bionix® Radiation Therapy
Toledo, Ohio based Bionix® Radiation Therapy provides innovative, quality, and precise products for brachytherapy, internal and external immobilization to the radiation therapy community. It has been collaborating with clinicians to create novel approaches for current challenges in radiation oncology and offer simple and effective solutions with patient outcome in mind. The Company is at the forefront of clinical technology and is taking a radical approach to treating highly complex cancers that require precision and accuracy. The Company's portfolio of brachytherapy products provides clinicians with the tools they need to treat cancer.
Last Close Stock Review
On Thursday, August 10, 2017, the stock closed the trading session at $96.65, marginally rising 0.47% from its previous closing price of $96.20. A total volume of 1.02 million shares have exchanged hands, which was higher than the 3-month average volume of 804.99 thousand shares. Varian Medical Systems' stock price rallied 0.25% in the last three months, 20.69% in the past six months and 14.63% in the previous twelve months. Furthermore, since the start of the year, shares of the Company have surged 21.57%. The stock is trading at a PE ratio of 31.06. At Thursday's closing price, the stock's net capitalization stands at $8.93 billion.
Pro-Trader Daily:
Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: [email protected]
Phone number: (917) 341.4653
Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Pro-Trader Daily